



July 22, 2025

KinoPharma, Inc.

## **Patent Approved for Novel Antiviral Drug for Bovine Papillomavirus Infection in Europe**

### **- Accelerating the Development of Drugs for Human and Bovine Papillomavirus Infections -**

KinoPharma Inc. (hereinafter referred to as "Kino") is pleased to announce here that as for our novel antiviral drug, a new use patent for the treatment of bovine papillomavirus (BPV) infection, has been newly granted in Europe, which means Kino has received the notice of allowance in patent examination by the European Patent Office. The patent registration is expected to be completed in several months. We plan to proceed with its patenting in other regions in the future.

The novel antiviral drug we are developing is a drug against human papillomavirus (HPV) based on a new concept that targets human host factors necessary for the transcription of viral DNA, and is being currently developed for the treatment of cervical intraepithelial neoplasia (CIN) and verruca vulgaris (or common warts) caused by HPV infection. We have been confirming that this novel antiviral drug is widely effective not only against HPV but also against other DNA viruses including BPV due to its versatile mechanism of action. Based on the granted patent and regionally expanded patents in the future for BPV infection, we have decided to add the new antiviral drug to our development pipeline for bovine papillomatosis and proceed with development of the relevant business.

---

#### **About Bovine Papillomavirus (BPV)**

BPV is a DNA virus that infects cattle and causes papillomas (warts). Currently, at least 15 types (BPV-1 to 15) are known, and each type of BPV is characterized by a different site of onset and lesion characteristics.

#### **About Bovine Papillomatosis**

Bovine papillomatosis is an infectious disease that causes papillomas (warts) to form on the teats, skin (head, neck, extremities, etc.) and mucous membranes (mouth, tongue, digestive tract, etc.) of cattle due to BPV infection. The incidence of bovine papillomatosis has been reported to range from a few percent to more than 50% depending on the region and farm, with many reports indicating a particularly high incidence in young cattle.

It has been reported that affected dairy cows suffer not only health problems due to mastitis, but also milking difficulties due to teat lesions, resulting in decreased work efficiency and deteriorated milk quality. It has also been reported that in beef cattle, in addition to a decrease in market value due to the cosmetic effects of affected lesions, the formation of papilloma can also affect growth and fattening by impairing feeding and exercise. The disease has a significant negative impact on dairy farmers and the livestock industry from both an economic and business perspective.

Currently, there is no established effective treatment for bovine papillomatosis, and the disease is mainly treated by resection of lesions and wait-and-see management. However, with the advent of effective therapeutic agents such as our drug, early intervention with such treatment is expected to prevent the spread of the disease, reduce the risk of recurrence, and improve milking efficiency.

### **About KinoPharma, Inc.**

KinoPharma is a biotech company engaged in research and development of novel antivirals through industry-academia collaboration with Kyoto University and other top-level of universities. It is involved in the development of new concept antiviral drugs that suppress viral replication by targeting host factors. In addition to developing drugs for various diseases caused by HPV infection, such as cervical intraepithelial tumor (CIN), a precancerous condition of cervical cancer, verruca vulgaris (or common warts), and condyloma acuminatum (or anogenital warts), the company is also developing the drugs for lethal viral infections and next-generation pandemic viral infections.

We believe that the patent for BPV infection is an important milestone in our development of antiviral drugs and will further accelerate our contribution to solving human and animal health issues.

---

### **Contact**

Corporate Administration Dept., KinoPharma, Inc.

E-mail: [info@kinopharma.com](mailto:info@kinopharma.com)

HP: <https://www.kinopharma.com/>